Vertex

Vertex, founded in 1989, is a prominent biotechnology company dedicated to developing and commercializing innovative medicines for serious diseases with significant unmet medical needs. The company focuses on small-molecule drugs and advanced genetic therapies, targeting conditions such as cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. By leveraging scientific innovation, Vertex continues to advance research programs in kidney disease, type 1 diabetes, and myotonic dystrophy, providing critical treatments to patients through a global network of healthcare providers, specialty pharmacies, and hospitals.

Operating with a workforce of 5,000-10,000 employees, Vertex maintains a robust operational footprint across 10 locations worldwide. The company’s strategic infrastructure supports its extensive R&D and commercialization efforts, ensuring efficient delivery of life-changing therapies. Learn about Vertex's global headquarters for detailed information regarding their geographic presence and operational facilities. This infrastructure is essential for maintaining their competitive edge in the biopharmaceutical sector, where they consistently push the boundaries of genetic research and clinical care to address complex health conditions.

Vertex demonstrates strong market performance, reporting annual revenue of $12.6B. The company competes with major industry players like Gilead Sciences, Regeneron, and Amgen, while maintaining a distinct focus on high-impact genetic disorders. Meet Vertex's team to learn about the leadership driving these scientific advancements, or Explore financial highlights for detailed metrics on their growth and funding history. Through continuous investment in discovery and development, Vertex remains a leader in the biotechnology industry, committed to transforming the lives of patients suffering from severe genetic and chronic diseases.